Irinotecan Liposomal Injection + Oxaliplatin + 5Fluorouracil + Leucovorin + Nab-paclitaxel + Gemcitabine
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Adenocarcinoma of the Pancreas
Conditions
Metastatic Adenocarcinoma of the Pancreas
Trial Timeline
Feb 11, 2020 → Feb 18, 2025
NCT ID
NCT04083235About Irinotecan Liposomal Injection + Oxaliplatin + 5Fluorouracil + Leucovorin + Nab-paclitaxel + Gemcitabine
Irinotecan Liposomal Injection + Oxaliplatin + 5Fluorouracil + Leucovorin + Nab-paclitaxel + Gemcitabine is a phase 3 stage product being developed by Ipsen for Metastatic Adenocarcinoma of the Pancreas. The current trial status is completed. This product is registered under clinical trial identifier NCT04083235. Target conditions include Metastatic Adenocarcinoma of the Pancreas.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04083235 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Adenocarcinoma of the Pancreas